# GTCR and ex-NuVasive chief launch Corza Medical via two-part deal

GTCR and former NuVasive CEO launched Corza Medical by acquiring Surgical Specialties and merging it with TachoSil, a carve-out from Takeda, creating a surgical technologies company with over $300 million in revenue.

- Type: Acquisition
- Announced: 2021-02-01
- Where: United States
- Status: completed
- Products: surgical technologies, surgical instruments
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Corza Medical](https://endata.com/companies/52955.md)
- [GTCR](https://endata.com/companies/8467.md) (investor)
- [Takeda Pharmaceutical](https://endata.com/companies/20775.md) (target)
- [Surgical Specialties Corporation](https://endata.com/companies/52511.md) (target)
- [Corza Medical](https://endata.com/companies/52955.md) (acquirer)
- [Takeda](https://endata.com/companies/52956.md) (target)

## Sources

- [pehub.com](https://www.pehub.com/gtcr-and-former-nuvasive-chief-launch-corza-medical-through-two-part-surgical-technology-deal/), 2021-02-01: "Corza Medical snaps up Surgical Specialties and merges it with TachoSil – a carve-out from Japan's Takeda – to create a $300 million-plus revenue generating surgical technologies company."
- [corza.com](https://corza.com/gtcr-and-gregory-t-lucier-announce-merger-of-surgical-specialties-and-tachosil-to-create-corza-medical/), 2021-02-01: "The formation of Corza Medical immediately creates a market-leading, surgical technology business that brings together brands with decades of trust and clinical relevance."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.